IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Rifampicin and Trimethoprim\Sulfamethoxazole plus intralesional antimony compared with antimony alone in treatment of cutaneous leishmaniasis.

Author: AHMED KAWEN, DR. WISAM MAJEED KATTOOF
Abstract: The present study was conducted to evaluate the efficacy of Rifampicin and Trimethoprim plus sodium stibogluconate antimony and sodium stibogluconate antimony in treatment of cutaneous leishmaniasis. This study was carried out on 89 patients were enrolled in the study and were divided into two groups; group A included 43 patients treated with Rifampin and Trimethoprim plus sodium stibogluconate antimony of them 19 males and 24 females, while group B included 46 patients(24 males and 22 females) treated with sodium stibogluconate antimony, all were treated and evaluated weekly. The cure rate in complete response for patients in group A in six week 35(81.39%) and less rate was in one week 1(2.23%) when as compared with group B which recorded high rate in six week 31(67.39%) while did not show any response in one week. The highest rate of partial response was observed in the first week 16(37.20%) and then reduced in the third week 12(27.90%) and sixth week 7(16.27%) while the percentage of partial response in group B was reduced when as compared with group A. The present study recorded that the poor response of combination therapy in group A was 26(60.46%) in the first week then gradually reduced in third and sixth week 4(9.30%) and 1(2.32%) respectively while the poor response in group B was high especially in the first week 45(97.82%) and third week 20(43.47%).The present study showed that using adjunct drug such as Rifampin and Trimethoprim plus sodium stibogluconate antimony increase the therapeutic activity in treatment of cutaneous leishmaniasis when as compared with sodium stibogluconate antimony alone.
Keyword: Cutaneous Leishmaniasis, Rifampicin and Trimethoprim,Antimony, Therapeutic Efficacy.
DOI: https://doi.org/10.31838/ijpr/2019.11.02.074
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477